OBJECTIVE: Behcet's disease (BD) is a systemic inflammatory disorder characterized by recurrent mucocutaneous ulcerations, ocular inflammation, and numerous severe systemic inflammatory manifestations. While most patients respond to standard immunosuppressive therapies, a subset will develop refractory disease. In this report, the use of a novel therapy for the treatment of BD is described. METHODS: Two patients with severe refractory BD who were treated with nonmyeloablative high-dose cyclophosphamide therapy without stem cell rescue. RESULTS: After treatment, both patients were completely weaned off immunosuppressive therapy and entered disease-free remissions of 18 and 24 months, respectively. CONCLUSIONS: These data suggest high-dose cyclophosphamide therapy without stem cell rescue as an alternative for the treatment of refractory BD.
OBJECTIVE:Behcet's disease (BD) is a systemic inflammatory disorder characterized by recurrent mucocutaneous ulcerations, ocular inflammation, and numerous severe systemic inflammatory manifestations. While most patients respond to standard immunosuppressive therapies, a subset will develop refractory disease. In this report, the use of a novel therapy for the treatment of BD is described. METHODS: Two patients with severe refractory BD who were treated with nonmyeloablative high-dose cyclophosphamide therapy without stem cell rescue. RESULTS: After treatment, both patients were completely weaned off immunosuppressive therapy and entered disease-free remissions of 18 and 24 months, respectively. CONCLUSIONS: These data suggest high-dose cyclophosphamide therapy without stem cell rescue as an alternative for the treatment of refractory BD.
Authors: Victor M Moyo; Douglas Smith; Isadore Brodsky; Pamela Crilley; Richard J Jones; Robert A Brodsky Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: A M Marmont; F Gualandi; G Piaggio; M Podestà; M Teresa van Lint; A Bacigalupo; F Nobili Journal: Bone Marrow Transplant Date: 2006-06 Impact factor: 5.483
Authors: Claudia Mendoza-Pinto; Mario García-Carrasco; Mario Jiménez-Hernández; Cesar Jiménez Hernández; Carlos Riebeling-Navarro; Arnulfo Nava Zavala; Mauricio Vera Recabarren; Gerard Espinosa; Javier Jara Quezada; Ricard Cervera Journal: Autoimmun Rev Date: 2009-10-30 Impact factor: 9.754
Authors: Christopher A Mecoli; Arash H Lahouti; Robert A Brodsky; Andrew L Mammen; Lisa Christopher-Stine Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-07-07